china_block_001_takeda_0

Takeda commits to advancing treatments for rare bleeding disorders and cancer

pharmafile | December 10, 2019 | News story | Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology 

Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to advancing treatments for rare bleeding disorders.

These scientific updates from the company showed off investigational and early-stage therapies as well as data from Phase 3 trials in disease states like leukemia and lymphoma.

Phil Rowlands, Takeda’s head at the Oncology Therapeutic Area Unit, said: “We are presenting notable data on several clinical programs at ASH, highlighting our deep oncology pipeline and our commitment to developing innovative therapies that may address unmet needs for blood cancer patients.”

Advertisement

Takeda also presented its portfolio of treatments for rare bleeding disorders, including haemophilia A, B and von Wilibrand disease. It presented updates to its gene therapy programmes designed to deal with these types of diseases.

Daniel Curran, Head of Takeda’s Rare Diseases Therapeutic Area Unit, said: “Understanding real-world evidence is critical as Takeda continues to provide patients with innovative therapies for hemophilia A and hemophilia B while broadening our research and development efforts in von Willebrand disease and other bleeding disorders.”

Conor Kavanagh

Related Content

Von Willebrand disease – increasing awareness and access to vital care

Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

drug-trials

Pharma&’s ovarian cancer therapy approved for use by NHS Scotland

Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …

The Gateway to Local Adoption Series

Latest content